Open AccessS216: CLINICAL ACTIVITY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1, OPEN‐LABEL STUDY
Author(s) -
Michot J.M.,
Chavez J. C.,
Carpio C,
Ferrari S.,
Feldman T. A.,
Morillo D.,
Kuruvilla J.,
Pinto A.,
Ribrag V.,
Bachy E,
Buchholz T. J.,
Carrancio S.,
Chou W.C.,
Guarinos C.,
Wu F.,
Li S.,
Patah P.,
Pourdehnad M.,
Nastoupil L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843756.99251.20
Subject(s) - medicine , tolerability , adverse effect , lymphoma , follicular lymphoma , oncology , dosing , bendamustine , gastroenterology , pharmacology , rituximab